Pharvaris NVNASDAQ:PHVS
- LAST PRICE7.3300
- TODAY'S CHANGE (%)-0.0900 (-1.2129%)
- Bid / Lots7.0000/ 2
- Ask / Lots7.4000/ 1
- Open / Previous Close7.3400 / 7.4200
- Day Range
- 52 Week Range
- Volume5,094
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PHVS |
|---|---|---|
| 10:48 ET | 400 | 7.3398 |
| 10:51 ET | 359 | 7.42 |
| 11:00 ET | 200 | 7.55 |
| 11:02 ET | 600 | 7.275 |
| 11:26 ET | 332 | 7.4 |
| 11:29 ET | 813 | 7.5 |
| 12:21 ET | 200 | 7.33 |
| 01:57 ET | 100 | 7.33 |
Mar 18, 2023
BRIEF-Pharvaris Says Positive Phase 2 Data From Rapide-1 Study Of Phvs416 For On-Demand Treatment Of HAE Attacks Highlighted At 2023 HAEi Regional Conference Apac, from 12:37AM ET on Saturday Mar 18, 2023 by Thomson Reuters
12:37AM ET on Saturday Mar 18, 2023 by Thomson ReutersPositive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC, from 12:35AM ET on Saturday Mar 18, 2023 by GlobeNewswire
12:35AM ET on Saturday Mar 18, 2023 by GlobeNewswire
Mar 2, 2023
Pharvaris to Present in Upcoming March Investor Conferences, from 6:50AM ET on Thursday Mar 02, 2023 by GlobeNewswire
6:50AM ET on Thursday Mar 02, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pharvaris NV | 250.5M | -4.1x | --- |
Immuneering Corp | 267.8M | -5.0x | --- |
Vaxxinity Inc | 272.3M | -3.4x | --- |
Kinnate Biopharma Inc | 266.4M | -2.3x | --- |
Atea Pharmaceuticals Inc | 263.4M | -2.2x | --- |
Outlook Therapeutics Inc | 259.2M | -3.2x | --- |
Company Information
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Contact Information
- Headquarters
- J.H. Oortweg 21LEIDEN, Netherlands 2333 CH
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer, Co-Founder, Executive Director
- Berndt Modig
- Co-Founder, Chief Operating Officer, Chief Scientific Officer
- Jochen Knolle
- Co-Founder, Non-Executive Director
- Hans Schikan
- Co-Founder, Chief Early Development Officer
- Anne Lesage
- Head of Finance, Principal Accounting Officer
- Anna Nijdam
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $250.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.80 |
Book Value | $6.67 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
